

**DECLARATION AND POWER OF ATTORNEY  
FOR PATENT APPLICATION**

As a below named inventor(s), I/We hereby declare that:

My/Our residence(s), post office address(es) and citizenship(s) are as stated below my name(s).

I/We verify believe I am/we are the original, first and sole/joint inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**NEW AGENTS FOR TRANSFERRING NUCLEIC ACIDS, COMPOSITIONS CONTAINING THEM AND  
THEIR USES**

and the specification of which  is attached hereto (Attorney Docket No. )  
(check one)  was filed on 02 Oct. 2000 as U.S. Application Number ST98009

and was amended on \_\_\_\_\_ (if applicable).  
 was described and claimed in PCT Int'l Application Number \_\_\_\_\_ filed on \_\_\_\_\_  
and as amended under PCT Article 19 on \_\_\_\_\_ (if any).

I/We hereby state that I/We have reviewed and understand the contents of the above identified specification, including the claims as amended by any amendment referred to above.

I/We acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 C.F.R. 1.56.

I/We hereby claim foreign priority benefits under Title 35, United States Code §119(a)-(d) or 365 (b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one other country other than the United States of America, listed below and having a filing date before that of the application on which priority is claimed. I/We have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Foreign Priority:	<u>FR98/04121</u>	<u>France</u>	<u>02 April 1998</u>
	Number	Country	Day/Month/Year Filed

Prior Foreign Appln(s):	<u>PCT/FR99/00740</u>	<u>PCT</u>	<u>30 March 1999</u>
	Number	Country	Day/Month/Year Filed

I/We hereby claim the benefit under Title 35, United States Code §119(e) of any United States Provisional application(s) listed below:

Number	Filing Date
--------	-------------

I/We hereby claim the benefit under Title 35, United States Code §120 or 365(c) of any United States application(s) or international application designating the United States listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I/We acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Application Serial No.	Filing Date	Status (Patented, Pending)
------------------------	-------------	----------------------------

I/We hereby appoint the attorneys and/or agents associated with the Customer No.(s) provided below as my/our attorneys and/or agents with full power to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

**Customer No.: 005487**

Send Correspondence to:

Karen I. Krupen  
Aventis Pharmaceuticals Products Inc.  
Rt. 202-206/Patent Dept.  
Bridgewater, New Jersey 08807

**Direct Telephone Calls to: 908-231-4658**

I/We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States code §1001, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Inventors(s):  Additional names and signatures are attached.1. Full name: Gerard BYKSignature: Gerard BykDate: 30 octobre 2000Country of Citizenship: IsraelResidence: Israel

(City and State/City and Country only)

P. O. Address: SAADIA GAON 3QYRIAT ONO 55513 Israel IL-X2. Full name: Marc FREDERICSignature: [Signature]Date: 25/10/00Country of Citizenship: FranceResidence: France

(City and State/City and Country only)

P. O. Address: 32 rue Denis Papin91220 BRETIGNY SUR ORGE, France FR-X

3. Full name: \_\_\_\_\_

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Country of Citizenship: \_\_\_\_\_

Residence: \_\_\_\_\_

(City and State/City and Country only)

P. O. Address: \_\_\_\_\_

\_\_\_\_\_

4. Full name: \_\_\_\_\_

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Country of Citizenship: \_\_\_\_\_

Residence: \_\_\_\_\_

(City and State/City and Country only)

P. O. Address: \_\_\_\_\_

\_\_\_\_\_

5. Full name: Daniel SCHERMANSignature: Daniel SchermanDate: 29 septembre 2000Country of Citizenship: FranceResidence: France

(City and State/City and Country only)

P. O. Address: 10 rue Erard75012 Paris, France FR-X6. Full name: Hans HOFLANDSignature: [Signature]Date: November 21, 2000Country of Citizenship: NetherlandsResidence: USA

(City and State/City and Country only)

P. O. Address: 126 Albacore LaneFoster City, CA 94404 CA

7. Full name: \_\_\_\_\_

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Country of Citizenship: \_\_\_\_\_

Residence: \_\_\_\_\_

(City and State/City and Country only)

P. O. Address: \_\_\_\_\_

\_\_\_\_\_

8. Full name: \_\_\_\_\_

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Country of Citizenship: \_\_\_\_\_

Residence: \_\_\_\_\_

(City and State/City and Country only)

P. O. Address: \_\_\_\_\_

\_\_\_\_\_

Aventis Pharmaceuticals Inc.

Patent Department

Route #202-206

P.O. Box 6800

Mail Code EMC-G1

Bridgewater, NJ 08807-0800

Telephone (908) 231-4658

Telefax (908) 231-2626